Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

D. M. Fraser, F. M. Sullivan, A. M. Thompson, C. McCowan (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    94 Citations (Scopus)
    220 Downloads (Pure)


    Background:Aspirin use has been associated with a reduced cancer incidence and fewer deaths from cancer. This study examined whether women with breast cancer prescribed aspirin postdiagnosis had improved survival.Methods:An observational, population cohort study was undertaken using data linkage of cancer registry, dispensed prescriptions and death records in Tayside, Scotland. All community prescriptions for aspirin in women with breast cancer were extracted and use postdiagnosis for each individual examined using Cox's proportional hazard models. The main outcome measures were all-cause mortality and breast cancer-specific mortality.Results:Four thousand six hundred and twenty-seven patients diagnosed with breast cancer between 1 January 1998 and 31 December 2008 were followed up until 28 February 2010. Median age at diagnosis was 62 (IQR 52-74). One thousand eight hundred and two (39%) deaths were recorded, with 815 (18%) attributed to breast cancer. One thousand and thirty-five (22%) patients were prescribed aspirin postdiagnosis. Such aspirin use was associated with lower risk of all-cause mortality (HR=0.53, 95% CI=0.45-0.63, P
    Original languageEnglish
    Pages (from-to)623-627
    Number of pages5
    JournalBritish Journal of Cancer
    Issue number3
    Early online date19 Jun 2014
    Publication statusPublished - 2014


    Dive into the research topics of 'Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study'. Together they form a unique fingerprint.

    Cite this